At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
AXR-270 Low Dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction
In Brief
A Phase 2 clinical trial evaluating AXR-270 Low Dose, AXR-270 High Dose, and 1 other intervention for Posterior Blepharitis and Meibomian Gland Dysfunction. Completed, enrolled 129 participants across 1 site.
Detailed Summary
This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosterior Blepharitis, Meibomian Gland Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJul 2020
Primary CompletionDec 2020
Study CompletionDec 2020
TodayJul 2026
First PostedJul 14, 2020
Enrollment StartJun 16, 2020
Primary CompletionDec 1, 2020
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.0 years ago
Interventions
AXR-270 Low Dosedrug
AXR-270 Topical Eyelid Cream
AXR-270 High Dosedrug
AXR-270 Topical Eyelid Cream
AXR-270 Vehicledrug
AXR-270 Topical Eyelid Cream Vehicle